Effect of the use of prediagnosis hormones on breast cancer prognosis: MCC-Spain study

Autor: Jéssica Alonso-Molero, Inés Gómez-Acebo, Javier Llorca, Virginia Lope-Carvajal, Pilar Amiano, Marcela Guevara, Vicente Martín, Gemma Castaño-Vinyals, María Fernández-Ortiz, Mireia Obón-Santacana, Juan Alguacil, Guillermo Fernandez-Tardon, Ana Molina-Barceló, Rafael Marcos-Gragera, Beatriz Pérez-Gómez, Amaia Aizpurua, Eva Ardanaz, Antonio J. Molina, Paz Rodríguez-Cundín, Víctor Moreno, Carmen Rodríguez-Reinado, Nuria Aragonés, Manolis Kogevinas, Marina Pollán, Trinidad Dierssen-Sotos
Rok vydání: 2022
Předmět:
Zdroj: MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
ISSN: 1072-3714
DOI: 10.1097/gme.0000000000002069
Popis: OBJECTIVE: To extend knowledge about the long-term use of hormones in hormone therapy or oral contraception as prognostic factors in breast cancer. METHODS: The MCC-Spain project is a cohort of 1,685 women with incident breast cancer recruited in Spain. Recruitment was carried out between 2007 and 2010, and the follow-up finished in December 2017. The impact of hormone therapy or oral contraception on breast cancer prognosis was analyzed considering year of birth and menopausal status (1,095 women [65%] were postmenopausal). Hazard ratios (HRs) were estimated using Cox regression models. Death by any cause was considered as the event, and hormone therapy or oral contraception were analyzed as regressors. RESULTS: Oral contraception use for less than 5 years shows an HR of 1.10 (95% CI, 0.75 to 1.62), whereas use for 5 or more years shows an HR of 1.46 (95% CI, 0.95 to 2.25), with a P trend of 0.01, showing a dose-dependent response. Regarding hormone therapy and restricting the analysis to postmenopausal women born between1940 and 1959, where most hormone therapy (consumption) is concentrated, the results did not show any trend. CONCLUSION: Concerning oral contraception use, our results demonstrate that their use is related to poor prognosis in breast cancer. However, research in this field is limited and controversial, indicating the need for more research in this area. Regarding hormone therapy consumption, our results indicate no association with better prognosis, which contradicts what has previously been published.
Databáze: OpenAIRE
Externí odkaz: